Unicycive Therapeutics, Inc.
Business
Unicycive Therapeutics is a clinical-stage biopharmaceutical company developing therapies for kidney disease. Its lead program, oxylanthanum carbonate, is a phosphate binder in late-stage development for hyperphosphatemia in dialysis patients. The second program, UNI-494, is a prodrug candidate for acute kidney injury in Phase 1 testing. Unicycive in-licenses drug candidates and pursues their development, regulatory approval, and commercialization, with focus on the U.S. market and partnerships in Greater China and select Asian markets.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 9 | 20 | 13 | 12 | 6 | |
| General and administrative | 20 | 12 | 9 | 7 | 3 | |
| Total operating expenses | 30 | 32 | 21 | 19 | 9 | |
| Loss from operations | −30 | −32 | −21 | −18 | −9 | |
| Interest income | 1 | 1 | 615,000 | — | — | |
| Interest expense | −71,000 | −71,000 | −82,000 | — | — | |
| Change in fair value of warrant liability | 2 | −6 | −10 | — | — | |
| Total other income (expenses) | 3 | −5 | −10 | −6,000 | −1 | |
| Net loss | −27 | −37 | −31 | −18 | −10 | |
| Unrealized loss on marketable securities, net | −1,000 | — | — | — | — | |
| Net comprehensive loss | −27 | −37 | — | — | — | |
| Dividend to Series B-1 preferred stockholders | — | −1 | −867,000 | — | — | |
| Net loss attributable to common stockholders | −27 | −38 | −31 | −18 | — | |
| Net loss per share attributable to common stockholders, basic (in Dollars per share) | −1.67 | −5.65 | −1.28 | −1.2 | −0.86 | |
| Net loss per share attributable to common stockholders, diluted (in Dollars per share) | −1.67 | −5.65 | −1.28 | −1.2 | −0.86 | |
| Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) | 16 | 7 | 25 | 15 | 12 | |
| Weighted-average shares outstanding used in computing net loss per share, diluted (in Shares) | 16 | 7 | 25 | 15 | 12 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 29 | 26 | — | 455,000 | 17 | |
| Prepaid expenses and other current assets | 8 | 5 | 4 | 2 | 2 | |
| Marketable securities | 12 | — | — | — | — | |
| Total current assets | 49 | 31 | 13 | 3 | 18 | |
| Right of use asset, net | 108,000 | 645,000 | 766,000 | 152,000 | 305,000 | |
| Property and equipment, net | 66,000 | 75,000 | 26,000 | 22,000 | 28,000 | |
| Total assets | 49 | 32 | 14 | 3 | 19 | |
| Accounts payable | 383,000 | 1 | 839,000 | 892,000 | 742,000 | |
| Accrued liabilities | 2 | 4 | 3 | 2 | 1 | |
| Warrant liability | 17 | 19 | 13 | — | — | |
| Operating lease liability - current | 117,000 | 564,000 | 327,000 | 155,000 | 151,000 | |
| Total current liabilities | 19 | 24 | 18 | 3 | 2 | |
| Operating lease liability long term | — | 117,000 | 466,000 | — | 155,000 | |
| Total liabilities | 19 | 24 | 18 | 3 | 2 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock, value | — | — | — | — | — | |
| Common stock, $0.001 par value per share 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | 22,000 | 11,000 | 35,000 | 15,000 | 15,000 | |
| Accumulated other comprehensive loss | −1,000 | — | — | — | — | |
| Additional paid-in capital | 158 | 109 | 61 | 34 | 32 | |
| Accumulated deficit | −128 | −101 | −65 | −34 | −16 | |
| Total stockholders equity | 30 | 7 | −4 | −466,000 | 16 | |
| Total liabilities and stockholders equity | 49 | 32 | 14 | 3 | 19 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 34,000 | 22,000 | 9,000 | 7,000 | 1,000 | |
| Stock-based compensation expense | 3 | 2 | 2 | 1 | — | |
| Amortization of operating lease right of use asset | 500,000 | 406,000 | 275,000 | 154,000 | 12,000 | |
| Prepaid expense and other current assets | −3 | −820,000 | −1 | 62,000 | — | |
| Accounts payable and accrued liabilities | −3 | 790,000 | 1 | 1 | 1 | |
| Operating lease liability | −565,000 | −397,000 | −252,000 | −151,000 | −12,000 | |
| Net cash used in operating activities | −31 | −29 | −18 | −16 | −6 | |
| Purchases of marketable securities | −12 | — | — | — | — | |
| Purchases of property and equipment | −24,000 | −72,000 | −12,000 | −2,000 | −29,000 | |
| Net cash used in investing activities | −12 | −72,000 | −12,000 | −2,000 | −29,000 | |
| Gross proceeds from secondary public offering | 47 | 683,000 | — | — | — | |
| Commissions paid on secondary public offering | −1 | — | — | — | — | |
| Deferred cost of at the market offering | — | −160,000 | — | — | — | |
| Payments on financed insurance policies | −212,000 | −527,000 | −496,000 | — | — | |
| Issuance costs related to issuance of Series B-1 preferred stock | — | −4 | — | — | — | |
| Proceeds from issuance of Series B-1 preferred stock | — | 50 | — | — | — | |
| Proceeds from exercise of warrants | 1 | — | — | — | — | |
| Dividends on preferred stock | — | −1 | — | — | — | |
| Net cash provided by financing activities | 46 | 45 | 28 | −471,000 | 22 | |
| Net increase in cash and cash equivalents | 3 | 16 | 9 | −16 | — | |
| Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock | — | 46 | — | — | — | |
| Deferred insurance charges included in prepaid expenses and other current assets | 332,000 | 267,000 | 270,000 | 240,000 | — | |
| Cash paid for interest | — | 12,000 | 24,000 | 6,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Unicycive Therapeutics, Inc.'s CIK number?
Unicycive Therapeutics, Inc.'s SEC CIK number is 0001766140 (1766140). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Unicycive Therapeutics, Inc.'s SEC filings?
All of Unicycive Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Unicycive Therapeutics, Inc. last report earnings?
Unicycive Therapeutics, Inc. (UNCY) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-054736). This is Unicycive Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Unicycive Therapeutics, Inc.'s most recent earnings 8-K?
Unicycive Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001213900-26-054736. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Unicycive Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →